



## **Trial Portfolio Update**

**Annual Scientific Meeting**

**12-15 March 2019**

# Contents

<b>Brain &amp; Central Nervous System .....</b>	<b>3</b>
<b>Breast.....</b>	<b>5</b>
<b>Head Neck and Skin.....</b>	<b>10</b>
<b>Gastrointestinal.....</b>	<b>14</b>
<b>Gynaecological .....</b>	<b>16</b>
<b>Lung.....</b>	<b>17</b>
<b>Lymphoma .....</b>	<b>20</b>
<b>Symptom Management.....</b>	<b>22</b>
<b>Urogenital (Bladder, Kidney &amp; Prostate) .....</b>	<b>23</b>
<b>Multiple tumour sites.....</b>	<b>27</b>

## ***Acknowledgements***

The TROG Central Operations Office would like to thank the trial chairs and the central coordinators for submitting the bi-annual progress reports.

# Brain & Central Nervous System

Trial in Development	
<b>TD 17.04</b>	<b>NEURONE: Intracranial stereotactic radiosurgery with or without memantine</b>

Trial Chairperson:

**Eric Hau**

Organisation: Westmead Hospital

Email address: [Eric.hau@health.nsw.gov.au](mailto:Eric.hau@health.nsw.gov.au)

Trial Contact:

**Rebecca Montgomery**

Organisation: TROG Cancer Research

Email address: [Rebecca.Montgomery@trog.com.au](mailto:Rebecca.Montgomery@trog.com.au)

**Phase:** II  
**Category:** A  
**Primary aim:** To test the hypothesis that addition of memantine will reduce the cognitive decline in patients treated with SRS for up to 10 metastases (each metastasis <3cm and total cumulate volume of BM ≤15ml)

Summary of Trial Activity:

eVote

Eol

Protocol  
Plan

Budget

Funding

Trials in Start-up	
<b>TD 18.06</b>	<b>FIG: FET PET in Glioma</b>

Trial Chairperson:

**Andrew Scott**

Organisation: Peter MacCallum Cancer Centre

Email address: [s](mailto:s)

Trial Contact:

**Rebecca Montgomery**

Organisation: TROG Cancer Research

Email address: [trials@trog.com.au](mailto:trials@trog.com.au)

**Phase:** II  
**Category:** A  
**Primary Aim:**

1. If initial staging FET-PET is an independent prognostic indicator of patient outcomes
2. To establish whether information from FET-PET can improve targeting of radiotherapy fields by delineating unresected disease;
3. To determine if in the post-therapy setting if FET-PET can differentiate tumour recurrence/disease progression from pseudoprogression

Summary of Trial Activity:

Protocol

HREC

Funding

RTQA  
In progress

Database  
In progress

Open Trial	
<b>TROG 15.02</b>	<b>ROAM: Radiation versus Observation following surgical resection of Atypical Meningioma: a randomised controlled trial</b>

Trial Chairperson:

**Gail Ryan**

Organisation: Peter MacCallum Cancer Centre

Email address: [gail.ryan@petermac.org](mailto:gail.ryan@petermac.org)

Trial Contact:

**Brita Lehmann**

Organisation: TROG Cancer Research

Email address: [ROAM@trog.com.au](mailto:ROAM@trog.com.au)

**Phase:** III

**Category:** B (Lead Group – the Walton Centre NHS Foundation Trust)

**Primary aim:** Time to MRI evidence of tumour recurrence or death due to any cause

**Accrual (Current / Target):** 21/190 Intl | **2/30 TROG**

**Site status:** 11 activated / 1 pending

**Projected accrual end date:** 01/07/2019

**Publications (2018):** Jenkinson M, Weber D, Haylock B, Sherratt F, Young B, Weller M, Bulbeck H, Culeddu G, Hughes D, Brain A, das K, Preusser M, Francis P, Gamble C. Letter to the editor response. Journal of Neurosurgery. 2018 Oct; 129(4):854-5.

**Closed to Accrual**

<b>TROG 06.01</b>	<b>Primary chemotherapy with temozolomide vs. radiotherapy in patients with low grade gliomas after stratification for genetic 1p loss: a phase III study</b>
-----------------------	---

Trial Chairpersons:

**Gail Ryan**

Organisation: Peter MacCallum Cancer Centre

Email address: [Gail.Ryan@petermac.org](mailto:Gail.Ryan@petermac.org)**Phase:** III**Category:** B (Lead Group - EORTC)**Primary aim:** The aim of this study is to demonstrate a difference in progression-free survival (PFS) for primary treatment with temozolomide versus primary irradiation**Final accrual:** 707 Intl | 69 TROG  
(EORTC 707 reg / TROG 69 reg, EORTC 473 rand / TROG 47 rand)**No of patients in f/up:** TROG 10 active & 12 survival only (10/03/2019)**Projected f/up end date:** 30/09/2020**Summary of activity (2018):** Follow-up continues**Publications (2018):** Nil

Trial Contact:

**Patrick Wheeler**

Organisation: TROG Cancer Research

Email address: [Patrick.Wheeler@trog.com.au](mailto:Patrick.Wheeler@trog.com.au)**Closed to Follow-up**

<b>TROG 08.02</b>	<b>A Randomised Phase III study of Temozolomide and short-course radiation versus short-course radiation alone in the treatment of newly diagnosed glioblastoma multiforme in elderly patients.</b>
-----------------------	---

Trial Chairpersons:

**Claire Phillips | Mike Fay**

Organisation: Peter MacCallum Cancer Centre | GenesisCare

Email address: [claire.phillips@petermac.org](mailto:claire.phillips@petermac.org) | [mikefay@me.com](mailto:mikefay@me.com)**Phase:** III**Category:** B (Lead Group - NCI CTG)**Primary aim:** To compare the overall survival (OS) rates between short-course radiation therapy alone and shortcourse radiation therapy given together with concurrent and adjuvant temozolomide.**Final accrual:** 560 Intl | 97 TROG**F/up end date:** 15/08/2016**Publications (2018)** Nil

## Breast

Trial in Development	
<b>TD 17.08</b>	<b>TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer</b>

Trial Chairpersons:

**Boon Chua**

Organisation: Prince of Wales Hospital

Email address: [Boon.Chua@health.nsw.gov.au](mailto:Boon.Chua@health.nsw.gov.au)

**Category:** B (Lead group - NCIC)

**Primary Aim:** To determine if omitting regional RT following breast conserving surgery (BCS) or mastectomy is not inferior to its use in women with 1-3 positive axillary nodes and ER-positive (ER+) biomarker low risk breast cancer.

Trial Contact:

**Rebecca Montgomery**

Organisation: TROG Cancer Research

Email address: [Rebecca.Montgomery@trog.com.au](mailto:Rebecca.Montgomery@trog.com.au)

Summary of Trial Activity:

eVote

EOI

GSA

Budget

Funding

Trial in Development	
<b>TD 17.07</b>	<b>Skagen Trial 1: Moderately hypofractionated loco-regional adjuvant radiation therapy of early breast cancer combined with a simultaneous integrated boost in patients with an indication for boost: DBCG HYPO II, a randomised clinically controlled trial</b>

Trial Chairpersons:

**Kirsty Stuart**

Organisation: Westmead Hospital

Email address: [Kirsty.Stuart@health.nsw.gov.au](mailto:Kirsty.Stuart@health.nsw.gov.au)

**Phase:** TBC

**Category:** B (Lead group - The Danish Group)

**Primary Aim:** The primary endpoint of the trial is radiation-induced late morbidity measured as lymph oedema of the arm on the treated side.

Trial Contact:

**Rebecca Montgomery**

Organisation: TROG Cancer Research

Email address: [Rebecca.Montgomery@trog.com.au](mailto:Rebecca.Montgomery@trog.com.au)

Summary of Trial Activity:

eVote

EOI

GSA

Budget

Funding

Open Trial	
<b>TROG 16.02</b>	<b>Local HER-O: A phase II pilot study of local therapy only (stereotactic radiosurgery and or surgery) for treatment of up to 5 brain metastases from HER2+ breast cancer</b>

Trial Chairperson:

**Claire Phillips**

Organisation: Peter MacCallum Cancer Centre

Email address: [Claire.Phillips@petermac.org](mailto:Claire.Phillips@petermac.org)

**Phase:** II

**Category:** A

**Primary Aim:** To assess the percentage of participants treated with whole brain radiotherapy within 12 months after completion of local therapy only for 1-5 previously untreated brain metastases from MHBC in women with metastatic HER2+ breast cancer who have good performance status and absent, controlled or treatable extracranial disease and are receiving HER2-targeted systemic therapy.

**Accrual (Current / Target):** 6/50

**Site status:** 4 activated / 7 pending

**Projected accrual end date:** 31/12/2019

**Publications (2018):** Nil

Trial Contact:

**Brita Lehman**

Organisation: TROG Cancer Research

Email address: [LocalHERO@trog.com.au](mailto:LocalHERO@trog.com.au)

Open Trial	
<b>TROG 12.02</b>	<b>PET LABRADOR: PET Scans for Locally Advanced Breast cancer and Diagnostic MRI to determine the extent of Operation and Radiotherapy</b>

Trial Chairperson:

**Verity Ahern**

Organisation: The Crown Princess Mary Cancer Centre, Westmead Hospital

Email address: [Verity.Ahern@health.nsw.gov.au](mailto:Verity.Ahern@health.nsw.gov.au)

**Phase:** II

**Category:** A

**Primary Aim:** The primary objective of the study is to demonstrate a LR rate of  $\leq 20\%$  at three years in patients who undergo BCS based on histopathology, MRI and PET-CT scans. (LR  $<10\%$  is expected).

**Accrual (Current / Target):** 14/220

**Site status:** 3 activated / 1 pending

**Projected accrual end date:** 31/07/2021

**Publications (2018):** Nil

Trial Contact:

**Tracy Pearl-Larson**

Organisation: The Crown Princess Mary Cancer Centre, Westmead Hospital

Email address: [Tracy.Pearl-Larson@health.nsw.gov.au](mailto:Tracy.Pearl-Larson@health.nsw.gov.au)

Closed to Accrual	
<b>TROG 11.01</b>	<b>SUPREMO: Radiation Therapy or Standard Therapy in Treating Women With Stage II Breast Cancer Who Have Undergone Mastectomy</b>

TROG Trial Chairperson:

**Boon Chua**

Organisation: Prince of Wales Hospital

Email address: [Boon.Chua@health.nsw.gov.au](mailto:Boon.Chua@health.nsw.gov.au)

**Phase:** III

**Category:** B (Lead Group - UK Medical Research Council)

**Primary aim:** To assess the role of adjuvant chest wall irradiation in 'intermediate risk' operable breast cancer following mastectomy

**Final accrual:** 1688 Intl | **24 TROG**

**No of patients in f/up:** 122 Intl | 19 TROG

**Projected f/up end date:** 31/05/2023

**Publications (2018):** Nil

Trial Contact:

**Rebecca Montgomery**

Organisation: TROG Cancer Research

Email address: [Rebecca.Montgomery@trog.com.au](mailto:Rebecca.Montgomery@trog.com.au)

# Closed to Accrual

**TROG  
08.06**

**STARS: A randomised comparison of anastrozole commenced before and continued during adjuvant radiotherapy for breast cancer versus anastrozole and subsequent anti-oestrogen therapy delayed**

Trial Chairperson:

**Peter Graham**

Organisation: St George Hospital

Email address: [Peter.Graham@health.nsw.gov.au](mailto:Peter.Graham@health.nsw.gov.au)

Trial Contact:

**Helen Cox**

Organisation: St George Hospital

Email address: [SESLHD-STARStrial@health.nsw.gov.au](mailto:SESLHD-STARStrial@health.nsw.gov.au)

**Phase:** III

**Category:** A

**Primary Aim:** This study compares the effectiveness of treatment with the drug anastrozole before and during adjuvant radiotherapy to anastrozole therapy delayed until after radiotherapy for women who have had a mastectomy or lumpectomy for breast cancer.

**Final Accrual:** 2023

**No of patients in f/up:** 1935

**Projected f/up end date:** 31/12/2026

**Summary of activity (2018):** Follow-up continuing

Upcoming: data clarification requests; preparation for publications.

**Publications (2018):** Nil

# Closed to Accrual

**TROG  
07.01**

**DCIS: A randomised phase III study of radiation doses and fractionation schedules for ductal carcinoma in situ (DCIS) of the breast**

Trial Chairperson:

**Boon Chua**

Organisation: Prince of Wales Hospital

Email address: [Boon.Chua@health.nsw.gov.au](mailto:Boon.Chua@health.nsw.gov.au)

Trial Contact:

**Tamica Humby**

Organisation: TROG Cancer Research

Email address: [DCIS@trog.com.au](mailto:DCIS@trog.com.au)

**Phase:** III

**Category:** A

**Primary Aim:** To assess if the addition of tumour bed boost after breast conserving surgery in women with non-low risk DCIS reduces the risk of local recurrence and if the risk of local recurrence in the shorter fractionation arm is not worse than that for the standard fractionation arm.

**Final Accrual:** 1608

**No of patients in f/up:** 1443

**Projected f/up end date:** 29/08/2024

**Publications (2018):** Nil

# Closed to Follow-up

**TROG  
14.04**

**HART: Deep Inhalation Breath Hold for reduction of cardiac toxicity in patients with left sided breast cancer undergoing radiotherapy**

Trial Chairperson:

**Tomas Kron**

Organisation: Peter MacCallum Cancer Centre

Email address: [Tomas.Kron@petermac.org](mailto:Tomas.Kron@petermac.org)

Trial Contact:

**Courtney Hill**

Organisation: TROG Cancer Research

Email address: [HART@trog.com.au](mailto:HART@trog.com.au)

**Phase:** II

**Category:** A

**Primary Aim:** To assess feasibility of Deep Inhalation Breath Hold (DIBH)

**Final Accrual:** 62

**F/up end date:** 21/12/2018

**Publications (2018):** Nil

Closed to Follow-up

**TROG  
10.02**

**RAPID: Randomized Trial of Accelerated Partial Breast Irradiation**

TROG Trial Chairperson:

**Boon Chua**

Organisation: Prince of Wales Hospital

Email address: [Boon.Chua@health.nsw.gov.au](mailto:Boon.Chua@health.nsw.gov.au)

Trial Contact:

**Rebecca Montgomery**

Organisation: TROG Cancer Research

Email address: [Rebecca.Montgomery@trog.com.au](mailto:Rebecca.Montgomery@trog.com.au)

**Phase:** III

**Category:** B (Lead Group Ontario Clinical Oncology Group[OCOG])

**Primary Aim:** To determine if accelerated partial breast irradiation using 3D CRT is as effective as whole breast irradiation following breast conserving surgery in women with ductal carcinoma in situ or early invasive breast cancer.

**Final Accrual:** 2135 Intl | **27 TROG**

**Publications (2018):** Nil

Closed to Follow-up

**TROG  
06.02**

**APBI: A Multicentre Feasibility Study of Accelerated Partial Breast Irradiation Using Three-Dimensional Conformal Radiation Therapy for Early Breast Cancer**

Trial Chairperson:

**Boon Chua**

Organisation: Prince of Wales Hospital

Email address: [Boon.Chua@health.nsw.gov.au](mailto:Boon.Chua@health.nsw.gov.au)

Trial Contact:

**Patrick Wheeler**

Organisation: TROG Cancer Research

Email address: [Patrick.Wheeler@trog.com.au](mailto:Patrick.Wheeler@trog.com.au)

**Phase:** II

**Category:** A

**Primary Aim:** A TROG multicentre feasibility study of APBI using 3D CRT in selected women with node-negative breast cancer treated by breast conserving surgery with negative margins

**Final Accrual:** 48

**F/up end date:** 07/08/2018

**Summary of activity (2018):** Last patient follow up completed August 2018

**Publications (2018):** Nil

Closed to Follow-up

**TROG  
03.05**

**MA.20: A phase III study of regional radiation therapy in early breast cancer to improve overall survival.**

TROG Trial Chairperson:

**Boon Chua**

Organisation: Prince of Wales Hospital

Email address: [Boon.Chua@health.nsw.gov.au](mailto:Boon.Chua@health.nsw.gov.au)

Trial Contact:

**Yvonne Murray**

Organisation: Canadian Cancer Trials Group

Email address: [ymurray@ctg.queensu.ca](mailto:ymurray@ctg.queensu.ca)

**Phase:** III

**Category:** B (Lead Group - Canadian Cancer Trials Group (CCTG))

**Primary Aim:** To determine if regional radiation therapy (to the ipsilateral supraclavicular, axillary and internal mammary nodes) in addition to breast radiation prolongs survival in women with early breast cancer compared with breast radiation alone.

**Final Accrual:** 1822 Intl | **180 TROG**

**F/up end date:** 16/12/2016

**Publications (2018):** Nil



Category C Trials		
TROG N°	TITLE	LEAD GROUP
ANZ 1601/BIG 16-02 EXPERT/ TROG 16.04	EXPERT: A randomised phase III trial of adjuvant radiotherapy versus observation following breast conserving surgery and endocrine therapy in patients with molecularly characterised low-risk luminal A early breast cancer	BCT

## Head Neck and Skin

Trial in Development	
<b>TD 18.05</b>	<b>ADHERE: A randomized phase III study on postoperative chemo- radiation durvalumab vs chemo-radiation placebo in subjects with HPV negative high risk squamous cell head and neck carcinoma (HNSCC)</b>

Trial Chairpersons:

**Sandro Porceddu**

Organisation: Princess Alexandra Hospital

Email address: [sandro.porceddu@health.qld.gov.au](mailto:sandro.porceddu@health.qld.gov.au)

Trial Contact:

**Rebecca Montgomery**

Organisation: TROG Cancer Research

Email address: [trials@trog.com.au](mailto:trials@trog.com.au)

**Category:** B

**Primary Aim:** To determine event-free survival with atezolizumab + 54 Gy radiation

Summary of Trial Activity:

eVote

EOI

GSA

Budget

Funding

Trial in Development	
<b>TD 18.03</b>	<b>Phase II exploratory trial of reduced dose radiation and atezolizumab in low risk HPV oropharyngeal squamous cell carcinoma (OPSCC) defined by &gt; 5% PDL1 positive intraepithelial immune cells</b>

Trial Chairpersons:

**Danny Rischin**

Organisation: Peter MacCallum Cancer Centre

Email address: [Danny.Rischin@petermac.org](mailto:Danny.Rischin@petermac.org)

Trial Contact:

**Rebecca Montgomery**

Organisation: TROG Cancer Research

Email address: [trials@trog.com.au](mailto:trials@trog.com.au)

**Category:** A

**Primary Aim:** To determine event-free survival with atezolizumab + 54 Gy radiation

Summary of Trial Activity:

eVote

EOI

GSA

Budget

Funding

Open Trial	
<b>TROG 17.10</b>	<b>reHUM: Re-analysis of the TROG 07.03 RadioHUM study using deformable image registration to predict patterns of failure in head and neck cancer patients undergoing treatment with IMRT or 3DCRT</b>

Trial Chairperson:

**Noel Ahern**

Organisation: Mid North Coast Cancer Institute, Coffs Harbour

Email address: [Noel.Ahern@NCAHS.health.nsw.gov.au](mailto:Noel.Ahern@NCAHS.health.nsw.gov.au)

**Phase:** Secondary Analysis

**Category:** D - secondary analysis

**Primary Aim:** To determine the patterns of failure in head and neck cancer patients receiving either 3DCRT or IMRT relative to specified target volumes and doses using post-recurrence imaging co-registered to the delivered treatment plan.

Closed to Accrual	
<b>TROG 14.03</b>	<b>EORTC1219: A blind randomized multicenter study of accelerated fractionated chemo-radiotherapy with or without the hypoxic cell radiosensitizer nimorazole (Nimoral), using a 15-gene signature for hypoxia in the treatment of squamous cell carcinoma of the head and neck</b>

Trial Chairpersons:

**Sandro Porceddu**

Organisation: Princess Alexandra Hospital

Email address: [Sandro.Porceddu@health.qld.gov.au](mailto:Sandro.Porceddu@health.qld.gov.au)

**Phase:** III

**Category:** B (lead Group-EORTC)

**Primary Aim:** To evaluate whether the hypoxic cell radiosensitizer nimorazole can improve the effect of primary curative accelerated fractionated concomitant chemo-radiotherapy with cisplatin and to investigate if patients who may have such benefit can be predicted by the use of a hypoxic gene profile.

**Final Accrual:** 194 of 240 (Int) / 12 of 60 (TROG)

**Projected f/up end date:** 31/12/2020

**Publications (2018):** Nil

Trial Contact:

**Patrick Wheeler**

Organisation: TROG Cancer Research

Email address: [EORTC1219@trog.com.au](mailto:EORTC1219@trog.com.au)

Closed to Accrual	
<b>TROG 12.01</b>	<b>HPV OROPHANYX: A Randomised Trial of Weekly Cetuximab and Radiation versus Weekly Cisplatin and Radiation in Good Prognosis Locoregionally Advanced HPV-Associated Oropharyngeal Squamous Cell Carcinoma</b>

Trial Chairpersons:

**Daniel Rischin | June Corry**

Organisation: Peter MacCallum Cancer Centre |

Genesis CancerCare

Email address: [Danny.Rischin@petermac.org](mailto:Danny.Rischin@petermac.org) | [June.Corry@genesiscare.com.au](mailto:June.Corry@genesiscare.com.au)

**Phase:** III

**Category:** A

**Primary Aim:** To compare symptom severity and distress between weekly cisplatin and RT versus weekly cetuximab and RT from baseline to 13 weeks post-completion of radiotherapy

**Final Accrual:** 189

**Projected f/up end date:** 23/08/2023

**Publications (2018):** Nil

Trial Contact:

**Anetta Matera**

Organisation: BaCT

Email address: [anetta.matera@petermac.org](mailto:anetta.matera@petermac.org)

Closed to Accrual	
<b>TROG 09.03</b>	<b>A phase II efficacy study of chemo-radiotherapy in PET stage II and III Merkel cell carcinoma of the skin</b>

Trial Chairpersons:

**Michael Poulsen**

Organisation: Radiation Oncology Services - Mater Centre

Email address: [Michael.Poulsen@health.qld.gov.au](mailto:Michael.Poulsen@health.qld.gov.au)

**Phase:** II

**Category:** A

**Primary Aim:** To investigate the efficacy and toxicity of a chemo-radiotherapy regimen of weekly carboplatin during radiation followed by adjuvant chemotherapy in Stage II-III MCC.

**Final Accrual (target):** 55

**No of patients in f/up:** 19

Trial Contact:

**Narelle Wallace**

Organisation: Mater Centre

Email address: [Narelle.Wallace@health.qld.gov.au](mailto:Narelle.Wallace@health.qld.gov.au)

**Projected f/up end date:** 28/02/ 2021

**Publications (2018):** Poulsen M, Macfarlane D, Veness M, Estall V, Hruby G, Kumar M, Pullar A, Tripcony L, Rischin D. Prospective analysis of the utility of 18-FDG PET in Merkel cell carcinoma of the skin: A Trans-Tasman Radiation Oncology Group Study, TROG 09:03. J Med Imag Radiat Oncol. 2018 Feb; 62(3):412-9.

**Closed to Follow-up**

<b>TROG 07.04</b>	<b>A Phase I/II trial of Cetuximab, Carboplatin and Radiotherapy for patients with locally advanced Head and Neck Squamous Cell Carcinoma</b>
-----------------------	---

**Trial Chairpersons:**

**Danny Rischin | June Corry**

**Organisation:** Peter MacCallum Cancer Centre | Genesis CancerCare

**Email address:** [Danny.Rischin@petermac.org](mailto:Danny.Rischin@petermac.org) | [June.Corry@genesiscare.com.au](mailto:June.Corry@genesiscare.com.au)

**Phase:** I/II

**Category:** A

**Primary Aim:** To show the feasibility and safety profile of the combination of cetuximab, carboplatin and RT in treatment of patients with LAHNC.

**Final Accrual (target):** 60 (60)

**F/up end date:** 1/12/2014

**Publications (2018)** Nil

**Closed to Follow-up**

<b>TROG 07.03</b>	<b>RadioHum: Radiotherapy with humidification in head and neck cancer. A randomized phase III trial of the Trans-Tasman Radiation Oncology Group in collaboration with Fisher and Paykel Healthcare</b>
-----------------------	---

**Trial Chairpersons:**

**Andrew Macann**

**Organisation:** Auckland Hospital

**Email address:** [AMacann@adhb.govt.nz](mailto:AMacann@adhb.govt.nz)

**Phase:** III

**Category:** A

**Primary Aim:** This trial evaluated prospectively the benefits of humidification in patients receiving radiotherapy / chemoradiation for head and neck cancer

**Final Accrual (target):** 210 (210)

**F/up end date:** 04/08/2013

**Publications (2018)** Nil

**Trial Contact:**

**Carol Fraser Brown**

**Organisation:** Auckland Hospital

**Email address:** [CarolFB@adhb.govt.nz](mailto:CarolFB@adhb.govt.nz)

**Closed to Follow-up**

<b>TROG 05.01</b>	<b>POST: Post-operative concurrent chemo-radiotherapy versus post-operative radiotherapy in high-risk cutaneous squamous cell carcinoma of the head and neck</b>
-----------------------	--

**Trial Chairpersons:**

**Sandro Porceddu**

**Organisation:** Princess Alexandra Hospital

**Email address:** [Sandro.Porceddu@health.qld.gov.au](mailto:Sandro.Porceddu@health.qld.gov.au)

**Phase:** III

**Category:** A

**Primary Aim:** To determine, in patients who have undergone surgery with curative intent for high-risk CSCC of the head and neck, whether there is a difference in time to locoregional

relapse between patients treated with post-operative concurrent chemo-radiotherapy and post-operative radiotherapy alone

**Final Accrual (target):** 321 (350)

**F/up end date:** 03/06/2016

**Publications (2018):** Porceddu S. Post-operative concurrent chemo-radiotherapy versus post-operative radiotherapy in high-risk cutaneous squamous cell carcinoma of the head and neck: A randomized Phase III trial (Trans-Tasman Radiation Oncology Group 05.01 Trial) - Post Operative Skin Trial (POST), J Clin Oncol. 2018 36:13, 1275-1283

#### Closed to Follow-up

<b>TROG 03.01</b>	<b>A randomised phase III study in advanced oesophageal carcinoma to compare dysphagia in patients treated with radiotherapy versus chemo-radiotherapy</b>
-------------------	--

Trial Chairpersons:

**Michael Penniment**

Organisation: Royal Adelaide Hospital

Email address: [Michael.Penniment@health.sa.gov.au](mailto:Michael.Penniment@health.sa.gov.au)

**Phase:** III

**Category:** A

**Primary Aim:** Relief of dysphagia

**Final Accrual (target):** 220

**F/up end date:** 01/03/2013

Trial Contact:

**Sonya Stephens**

Organisation: Royal Adelaide Hospital

Email address: [Sonya.Stephens@health.sa.gov.au](mailto:Sonya.Stephens@health.sa.gov.au)

**Publications (2018):** Penniment M, De Ieso P, Harvey J, Stephens S, Au H, O'Callaghan C, Kneebone A, Ngan S, Ward I, Roy R, Smith J, Nijjar T, Biagi J, Mulroy L, Wong R; TROG 03.01/CCTG ES.2 group. Palliative chemoradiotherapy versus radiotherapy alone for dysphagia in advanced oesophageal cancer: a multicentre randomised controlled trial (TROG 03.01). Lancet Gastroenterol Hepatol. 2018 Feb; 3(2):114-24.

#### Category C Trials

<b>TROG N°</b>	<b>TITLE</b>	<b>LEAD GROUP</b>
08.05	<b>WBRTMel:</b> Whole Brain Radiotherapy following local treatment of intracranial metastases of melanoma-A randomised phase III trial	ANZMTG
17.11	<b>cPOST:</b> A randomised, placebo-controlled, double-blind study of adjuvant Cemiplimab versus placebo after surgery and radiation therapy in patients with high risk cutaneous squamous cell carcinoma	REGENERON
08.09	<b>RTN2:</b> A randomised trial of post operative radiation therapy following wide excision of neurotropic melanoma of the head and neck	ANZMTG

## Gastrointestinal

### Trial in Development

**TD**  
**16.05**

#### ACT 5: Personalising Radiotherapy Dose in Anal Cancer

Trial Chairpersons:

**Mark Lee**

Organisation: Liverpool Hospital

Email address: [mark.lee@health.nsw.gov.au](mailto:mark.lee@health.nsw.gov.au)

Phase: II/III

Category: B (Lead group - NCRI)

**Primary Aim:** To assess the 3-year locoregional failure rate in participants with anal margin tumours who have been treated by LE with selective lower-dose CRT.

Trial Contact:

**Rebecca Montgomery**

Organisation: TROG Cancer Research

Email address: [Rebecca.Montgomery@trog.com.au](mailto:Rebecca.Montgomery@trog.com.au)

Summary of Trial Activity:

eVote

EOI

GSA

Budget

Funding

### Trials in Start up

**TD**  
**17.03**

#### LARK: Liver Ablative Radiotherapy utilizing Kilovoltage intrafraction monitoring (KIM)

Trial Chairperson:

**Dominique Lee | Tim Wang**

Organisation: Calvary Mater | Westmead

Email address: [Dominique.Lee@calvarymater.org.au](mailto:Dominique.Lee@calvarymater.org.au) | [tim.wang1@health.nsw.gov.au](mailto:tim.wang1@health.nsw.gov.au)

Phase: II

Category: A

**Primary Aim:** Quantify accumulated patient dose distribution with the KIM intervention compared to dose distribution estimated without the KIM intervention.

Trial Contact:

**Brita Lehmann**

Organisation: TROG Cancer Research

Email address: [brita.lehmann@trog.com.au](mailto:brita.lehmann@trog.com.au)

Summary of Trial Activity:

Protocol

HREC

Funding

RTQA

Database

### Closed to Follow-up

**TROG**  
**09.01**

#### A phase II trial of integrated preoperative radiotherapy and chemotherapy with oxaliplatin 5-FU and folinic acid in patients with locally advanced rectal cancer

Trial Chairperson:

**Sam Ngan**

Organisation: Peter MacCallum Cancer Centre

Email address: [Sam.ngan@petermac.org](mailto:Sam.ngan@petermac.org)

Phase: II

Category: A

**Primary Aim:** Tolerability rate

**Final Accrual (target):** 41

**F/up end date:** 07/08/2012

**Publications (2018):** Nil

Category C Trial		
TROG N°	TITLE	LEAD GROUP
AG0118PS/ TD18.04	<b>MASTERPLAN:</b> Mfolfirinox And STereotactic Radiotherapy for Pancreatic cancer with Locally AdvaNced disease (MASTERPLAN): randomised study from the Australian Gastrointestinal trials Group (AGITG)	AGITG
8.08	TOPGEAR: A randomised phase II/III trial of preoperative chemoradiotherapy Versus preoperative chemotherapy for resectable gastric cancer.	AGITG

## Gynaecological

Closed to Follow-up

<b>TROG 04.02</b>	<b>Prospective Study to Determine the Relationships Between Survival and FIGO Stage, Tumour Volume and Corpus Invasion in Cervical Cancer</b>
-----------------------	---

Trial Chairpersons:

**Farshad Foroudi | Gerard Adams**

Trial Contact:

**Patrick Wheeler**

Organisation: TROG Cancer Research

Email address: [Patrick.wheeler@trog.com.au](mailto:Patrick.wheeler@trog.com.au)

**Phase:** Prospective follow up study

**Category:** A

**Primary Aim:** The principal aim of the study is to assess the independent prognostic significance, with respect to overall survival, of the factors, FIGO stage, tumour volume and corpus invasion, in radically treated cervical cancer patients.

**Final Accrual (target):** 108

**F/up end date:** 15/05/2014

**Publications (2018):** Nil

### Category C Trial

TROG N°	TITLE	LEAD GROUP
08.04	<b>PORTEC:</b> Randomised phase III trial comparing concurrent chemoradiation and adjuvant chemotherapy with pelvic radiation alone in high risk and advanced stage endometrial carcinoma	Dutch Cooperative Gynaecologic Oncology Group   ANZGOG



## Lung

### Trials in Development

<b>TD 17.01</b>	<b>DESSERT: Decision Support Systems for Radiation Therapy in Non-Small Cell Lung Cancer</b>
---------------------	--

Trial Chairperson:

**Shalini Vinod**

Organisation: Liverpool Hospital

Email address: [shalini.vinod@health.nsw.gov.au](mailto:shalini.vinod@health.nsw.gov.au)

Trial Contact:

**Patrick Wheeler**

Organisation: TROG Cancer Research

Email address: [Patrick.Wheeler@trog.com.au](mailto:Patrick.Wheeler@trog.com.au)

**Phase:** III

**Category:** A

**Primary Aim:** To evaluate the impact of a Decision Support System (DSS) on radiotherapy treatment aligned with a patient's individual prognostic profile

**Summary of Trial Activity:**

eVote

Eol

Protocol  
Plan

Budget

Funding

### Trial in Development

<b>TD 13.03</b>	<b>SABR OS: Surgery or Stereotactic Ablative Body Radiotherapy (SABR) For Early Stage Peripheral Non-Small Cell Lung Cancer (NSCLC) in Patient's Considered at Higher Risk of Surgical Resection</b>
---------------------	--

Trial Chairperson:

**Fiona Hegi-Johnson**

Organisation: Peter MacCallum Cancer Centre

Email address: [fiona.hegi-johnson@petermac.org](mailto:fiona.hegi-johnson@petermac.org)

Trial Contact:

**Brita Lehmann**

Organisation: TROG Cancer Research

Email address: [SABROS@trog.com.au](mailto:SABROS@trog.com.au)

**Phase:** II

**Category:** Downgraded to Project.

**Primary Aim:** To assess the rate of recruitment, compliance, and ability to deliver SABR in patients with early stage lung cancer patients with peripheral lesions who are at intermediate risk of morbidity and mortality after surgery.

**Summary of Trial Activity:**

eVote

Eol

Protocol  
Plan

Budget

Funding

### Open Trial

<b>TROG 17.02</b>	<b>OUTRUN: A randomised phase II trial of Osimertinib with or without stereotactic radiosurgery for EGFR mutated NSCLC with brain metastases</b>
-----------------------	--

Trial Chairpersons:

**Fiona Hegi-Johnson | Chee Lee**

**Yu Yang Soon | Ivan Tham | Ross Soo**

Organisation: Peter MacCallum Cancer Centre

| St George | National University Hospital

Trial Contact:

**Patrick Wheeler**

Organisation: TROG Cancer Research

Email address: [OUTRUN@trog.com.au](mailto:OUTRUN@trog.com.au)

**Phase:** II

**Category:** A

**Accrual Target:** 0/80

**Projected accrual end date:** 2022

**Primary Aim:** To assess the efficacy of Osimertinib with deferred local brain metastases directed therapies compared with upfront SRS followed by Osimertinib by assessment of intracranial progression free survival at 12 months

# Closed to Accrual

<b>TROG 13.01</b>	<b>SAFRON II: Stereotactic Ablative fractionated radiotherapy versus radiosurgery for oligometastatic neoplasia to the lung: A randomised Phase II trial</b>
-----------------------	--

Trial Chairperson:

**Shankar Siva**

Organisation: Peter MacCallum Cancer Centre

Email address: [shankar.siva@petermac.org](mailto:shankar.siva@petermac.org)

**Phase:** II

**Category:** A

**Primary Aim:** To assess multi fraction versus single fraction SABR in lung metastases

**Final Accrual :** 90

**Projected f/up end date:** 31/07/2020

**Publications (2018):** Nil

Trial Contact:

**Brita Lehmann**

Organisation: TROG Cancer Research

Email address: [SAFRONII@trog.com.au](mailto:SAFRONII@trog.com.au)

# Closed to Follow-up

<b>TROG 09.02</b>	<b>CHISEL: A randomised phase III trial of highly conformal hypofractionated image guided ("Stereotactic") radiotherapy (HypoRT) versus conventionally fractionated radiotherapy (ConRT) for inoperable early stage I non small cell lung cancer</b>
-----------------------	--

Trial Chairpersons:

**David Ball**

Organisation: Peter MacCallum Cancer Centre

email address: [David.Ball@petermac.org](mailto:David.Ball@petermac.org)

**Phase:** III

**Category:** A

**Primary Aim:** Time to local failure

**Final Accrual** 101

**Publications (2018):** Kron T, Chesson B, Hardcastle N, Crain M, Clements N, Burns M, Ball D. Credentialing of radiotherapy centres in Australasia for TROG 09.02 (Chisel) a Phase III clinical trial on stereotactic ablative body radiotherapy of early stage lung cancer. Br J Radiol. 2018 Mar; 91(1085):20170737

Trial Contact:

**Janani Sivasuthan**

Organisation: BaCT

email address: [Janani.Sivasuthan@petermac.org](mailto:Janani.Sivasuthan@petermac.org)

## Closed to Follow-up

<b>TROG 11.03</b>	<b>PLUNG GP: A Randomised Phase III trial of high dose palliative radiotherapy (HDPRT) vs Concurrent chemotherapy + HDPRT (C-HDPRT) in patients with good performance status, locally advanced or metastatic NSCLC with symptoms predominantly due to intrathoracic disease who are not suitable for radical chemo-radiotherapy</b>
-------------------	---

Trial Chairperson:

**Margot Lehman**

Organisation: Princess Alexandra Hospital

Email address: [margot.lehman@health.qld.gov.au](mailto:margot.lehman@health.qld.gov.au)

Trial Contact:

**Adrienne See**

Organisation: Princess Alexandra Hospital

Email address: [adrienne.see@health.qld.gov.au](mailto:adrienne.see@health.qld.gov.au)

**Phase:** III

**Category:** A

- Primary Aim:** To compare, in this group of patients, high dose palliative radiotherapy (HDPRT) versus concurrent chemotherapy and HDPRT (C-HDPRT), with respect to
- The relief of dyspnoea, cough, haemoptysis and chest pain as assessed by change in total symptom burden from baseline to six weeks after the completion of treatment.
  - Response for each component symptom separately (dyspnoea, cough, haemoptysis, chest pain)

**Final Accrual :** 76/130

**Publications (2018):** Nil

## Category C Trials

<b>TROG N°</b>	<b>TITLE</b>	<b>LEAD GROUP</b>
17.09	<b>STIMULI:</b> A randomised open-label phase II trial of consolidation with nivolumab and ipilimumab in limited-stage SCLC after chemo-radiotherapy	ALTG
16.01	<b>NIVORAD:</b> Randomised phase 2 trial of nivolumab and radiotherapy versus nivolumab alone in advanced non-small cell lung cancer progressing after first line chemotherapy	ALTG

# Lymphoma

Closed to Follow-up	
<b>TROG 05.02</b>	<b>A prospective single arm trial of involved field radiotherapy alone for stage I-II low grade non-gastric marginal zone lymphoma</b>

Trial Chairpersons:

**Michael MacManus**

Organisation: Peter MacCallum Cancer Centre

Email address: [Michael.MacManus@petermac.org](mailto:Michael.MacManus@petermac.org)

Trial Contact:

**Marijana Vaneski**

Organisation: BaCT

Email address: [marijana.vanevski@petermac.org](mailto:marijana.vanevski@petermac.org)

**Phase:** II

**Category:** A

**Primary Aim:** This prospective study will test the following hypotheses in patients with stage I-II low grade non-gastric marginal zone (MZ) lymphoma:

- Involved Field Radiotherapy will produce a complete response rate of > 90%
- Radiotherapy will be associated with a locoregional progression of < 20% after 10 years
- Death from non-gastric MZ lymphoma will occur in < 40% of patients within 10 years of radiotherapy

**Final Accrual (target):** 70 (100)

**F/up end date:** 24/04/17

**Publications (2018):** Nil

Closed to Follow-up	
<b>TROG 01.02</b>	<b>PCNSL: A Phase II Study of Idarubicin-Based Combined Modality Therapy in Primary Central Nervous System Lymphoma</b>

Trial Chairperson:

**Peter O'Brien**

Organisation: Genesis Cancer Care

Email address: [Peter.O'Brien@genesiscare.com.au](mailto:Peter.O'Brien@genesiscare.com.au)

Trial Contact:

**Sarah Gallagher**

Organisation: Calvary Mater Hospital

**Phase:** II

**Category:** A

**Primary Aim:** To estimate the median and 2-year overall survival. To estimate the risk of late neurotoxicity relative to results achieved in TROG 92.01.

**Final Accrual (target):** 20 (53)

**F/up end date:** 08/08/2013

**Publications (2018):** Nil

Closed to Follow-up	
<b>TROG 99.03</b>	<b>A Randomised Multicentre Trial of Involved Field Radiotherapy Versus Involved Field Radiotherapy Plus Chemotherapy in combination with Rituximab (MabThera®) For Stage I – II Low Grade Follicular Lymphoma</b>

Trial Chairperson:

**Michael MacManus**

Organisation: Peter MacCallum Cancer Centre

Email address: [Michael.MacManus@petermac.org](mailto:Michael.MacManus@petermac.org)

**Phase:** III

**Category:** A

**Primary Aim:** To test the hypothesis that the addition of six cycles of systemic therapy as specified in the protocol will improve progression-free survival for patients with stage I and II low-grade follicular lymphoma treated with involved-field radiotherapy (IFRT).

**Final Accrual (target):** 150 (200)

**Publications (2018):** MacManus M. A Randomized Trial of Systemic Therapy after involved-field Radiotherapy in patients with Early Stage Follicular Lymphoma: TROG 99.03. J Clin Oncol. 2018 Oct; 36(29):2918-2925.

Category C Trials		
TITLE	LEAD GROUP	LEAD GROUP
03.03	<b>HDNHL04:</b> An ALLG/TROG Prospective Multicentre Study of Involved-Field Radiotherapy with Transplantation for Patients with Hodgkin's Disease and non-Hodgkin's Lymphoma	ALLG

## Symptom Management

### Open Trial

<b>TROG 17.06</b>	<b>SC.24: A Phase III Randomized Feasibility Study Comparing Stereotactic Body Radiotherapy (SBRT) Versus Conventional Palliative Radiotherapy (CRT) For Patients With Spinal Metastases</b>
-----------------------	--

Trial Chairperson:

**Shankar Siva**

Organisation: Peter MacCallum Cancer Centre

Email address: [shankar.siva@petermac.org](mailto:shankar.siva@petermac.org)

Trial Contact:

**Courtney Hill**

Organisation: TROG Cancer Research

email address: [SC24@trog.com.au](mailto:SC24@trog.com.au)

**Phase:** II

**Category:** B (Lead group - CCTG)

**Primary Aim:** To assess complete pain response in the treatment area at 3 months post-radiation.

**Accrual (Current/Target)::** 197/228 (Intl) | 10/35 (TROG)

**Projected accrual end date:** 30/05/ 2019

**Site status:** 3 activated / 4 pending / 1 withdrawn (Nepean)

### Closed to Follow-up

<b>TROG 11.02</b>	<b>SCORAD III : A randomised phase III study of single fraction radiotherapy compared to multifraction radiotherapy in patients with metastatic spinal cord compression</b>
-----------------------	---

Trial Chairperson:

**Tanya Holt**

Organisation: Radiation Oncology Services - Mater Centre

Email address: [Tanya.Holt@health.qld.gov.au](mailto:Tanya.Holt@health.qld.gov.au)

**Phase:** III

**Category:** B (Lead Group - University College London)

**Primary Aim:** To show that ambulatory status using 8Gy in 1 fraction is no worse than with 20Gy in 5 fractions for patients with metastatic spinal cord compression (SCC).

**Final Accrual (target):** 694 (700) Int | 33 (20) TROG

**F/up end date:** 30/04/2017

**Publications (2018):** Nil

# Urogenital (Bladder, Kidney & Prostate)

Open Trial	
<b>TROG 18.01</b>	<b>NINJA: Novel Integration of New prostate radiation schedules with adjuvant Androgen deprivation</b>

Trial Chairperson:

**Jarad Martin | Mark Sidhom**

Organisation: Calvary Mater Newcastle

Email address: [Jarad.Martin@calvarymater.org.au](mailto:Jarad.Martin@calvarymater.org.au)

Trial Contacts:

**Jo Smart and Tess Vuong**

Organisation: Calvary Mater and Liverpool

Email address: [NinjaTrial@calvarymater.org.au](mailto:NinjaTrial@calvarymater.org.au)

**Phase:** II-III

**Category:** A

**Primary Aim:** Prostate cancer biochemical control measured by Phoenix definition of nadir + 2ng/mL and/or detection of metastases or initiation of salvage intervention by the 5 year time point

**Accrual Target :** 150 (ph. II)

Open Trial	
<b>TROG 15.03</b>	<b>FASTRACK II: Focal Ablative STereotactic RADiosurgery for Cancers of the Kidney, a Phase II Clinical Trial</b>

Trial Chairperson:

**Shankar Siva**

Organisation: Peter MacCallum Cancer Centre

Email address: [shankar.siva@petermac.org](mailto:shankar.siva@petermac.org)

Trial Contact:

**Courtney Hill**

Organisation: TROG Cancer Research

Email address: [FASTRACKII@trog.com.au](mailto:FASTRACKII@trog.com.au)

**Phase:** II

**Category:** A

**Primary Aim:** To estimate the efficacy of SABR for primary Renal Cell Carcinoma

**Accrual (Current / Target):** 42/70

**Site status:** 7 activated / 4 pending / 1 withdrawn

**Projected accrual end date:** 01/07/2019

**Publications (2018):** Nil

Open Trial	
<b>TROG 14.02</b>	<b>RAIDER: A randomised phase III trial of adaptive image guided standard or dose escalated radiotherapy in the treatment of transitional cell carcinoma of the bladder</b>

Trial Chairperson:

**Farshad Foroudi**

Organisation: The Austin

Email address: [farshad.foroudi@austin.org.au](mailto:farshad.foroudi@austin.org.au)

Trial Contact:

**Patrick Wheeler**

Organisation: TROG Cancer Research

Email address: [RAIDER@trog.com.au](mailto:RAIDER@trog.com.au)

**Phase:** III

**Category:** B (Lead Group - ICR)

**Primary Aim:** **Stage I:** The primary objective of stage I is to ensure that the dose escalated (DART) treatment can be planned and delivered at multiple centres within safe dose constraints

**Stage II:** Stage II aims to ensure the proportion of patients experiencing severe or medically significant late toxicity as a result of DART treatment is within acceptable limits.

**Accrual (Current / Target):** 220/240 Intl | 21/30 TROG

**Site status:** 10 activated / 1 to be withdrawn

**Projected accrual end date:** 31/07/2019

**Publications (2018):** Nil

Closed to Accrual	
<b>TROG 15.01</b>	<b>SPARK: Stereotactic Prostate Adaptive Radiotherapy utilising KIM (Kilovoltage Intrafraction Monitoring)</b>

Trial Chairpersons:

**Jarad Martin | Paul Keall**

Organisation: Calvary Mater Newcastle | University of Sydney

Email address: [jarad.martin@calvarymater.org.au](mailto:jarad.martin@calvarymater.org.au) | [paul.keall@sydney.edu.au](mailto:paul.keall@sydney.edu.au)

**Phase:** II

**Category:** A (Sponsor USyd)

**Primary Aim:** Quantify accumulated patient dose distributions with the KIM intervention compared to dose distributions estimated without the KIM intervention.

**Final Accrual :** 49

**Projected f/up end date:** 30/04/2020

- Publications (2018):**
- Keall P, Nguyen D, O'Brien R, Caillet V, Hewson E, Poulsen P, Bromley R, Bell L, Eade T, Kneebone A, Martin J, Booth J. The first clinical implementation of real-time image-guided adaptive radiotherapy using a standard linear accelerator. *Radiother Oncol.* 2018 Apr; 127(1):6-11.
  - Kim J, Nguyen D, Booth J, Huang C, Fuangrod T, Poulsen P, O'Brien R, Caillet V, Eade T, Kneebone A, Keall P. The accuracy and precision of Kilovoltage Intrafraction Monitoring (KIM) six degree-of-freedom prostate motion measurements during patient treatments. *Radiother Oncol.* 2018 Feb; 126(2):236-43.

Trial Contact:

**Brita Lehmann**

Organisation: TROG Cancer Research

Email address: [SPARK@trog.com.au](mailto:SPARK@trog.com.au)

Closed to Accrual	
<b>TROG 08.03</b>	<b>RAVES: A phase III multi-centre randomised trial comparing adjuvant radiotherapy (RT) with early salvage RT in patients with positive margins or extraprostatic disease following radical prostatectomy</b>

Trial Chairperson:

**Maria Pearse**

Organisation: Auckland Hospital

Email address: [mariap@adhb.govt.nz](mailto:mariap@adhb.govt.nz)

**Phase:** III

**Category:** A

**Primary Aim:** To test the hypothesis that active surveillance with early salvage radiotherapy can be considered non-inferior to standard treatment with adjuvant (immediate) radiotherapy with respect to risk of biochemical failure (bF) in patients with pT3 disease and/or positive margins following RP.

**Final Accrual (target):** 333 (470)

**No of patients in f/up:** 305

**Projected f/up end date:** 30/06/2022

**Summary of activity (2018):** Analysis of primary and secondary endpoints is underway. RAVES Trial Mangement held a preliminary meeting on 1/12/18 to discuss potential publication strategies. The RAVES TMC will meet at the TROG ASM on 14/3/19 to review initial analysis results and further develop publication ideas

**Publications (2018):** Nil

Trial Contact:

**Carol Fraser-Browne**

Organisation: Auckland Hospital

Email address: [carolFB@adhb.govt.nz](mailto:carolFB@adhb.govt.nz)



Closed to Follow-up	
<b>TROG 10.01</b>	<b>BOLART: A multicentre feasibility study of online adaptive image guided radiotherapy for muscle invasive bladder cancer</b>

Trial Chairperson:

**Farshad Foroudi**

Organisation: The Austin

Email address: [farshad.foroudi@austin.org.au](mailto:farshad.foroudi@austin.org.au)

**Phase:** Feasibility

**Category:** A

**Primary Aim:** The overall objective is to determine whether online adaptive image guided radiotherapy is feasible in multiple radiation oncology centres of varying size in Australia and New Zealand.

**Final Accrual (target):** 54 (50)

**F/up end date:** 18/06/2015

**Publications (2018):** Nil

Closed to Follow-up	
<b>TROG 08.01</b>	<b>PROFIT: A randomised trial of shorter radiation fractionation schedule for the treatment of localised prostate cancer (Prostate Fractionated Irradiation Trial)</b>

Trial Chairperson:

**Jarad Martin**

Organisation: Calvary Mater Newcastle

Email address: [jarad.martin@calvarymater.org.au](mailto:jarad.martin@calvarymater.org.au)

**Phase:** III

**Category:** B (Lead Group – CCTG)

**Primary Aim:** To compare the efficacy of a shorter course of radiotherapy (6000cGy in 20 fractions over 4 weeks) with a conventional fractionation course (7800cGy in 39 fractions over 8 weeks) with respect to biochemical-clinical failure (BCF)

**Final Accrual :** 1206) Intl | **207TROG**

**F/up end date:** 31/05/2017

**Summary of activity (2017):** Study closed to follow up as of 31/05/2017. The data has been cleaned and the analysis is in progress. CCTG are in process of closing out the study

**Publications (2018):** Nil

Trial Contact:

**Rebecca Montgomery**

Organisation: TROG Cancer Research

Email address: [Rebecca.montgomery@trog.com.au](mailto:Rebecca.montgomery@trog.com.au)

Closed to Follow-up	
<b>TROG 03.04</b>	<b>RADAR: A Randomised Trial Investigating the Effect on Biochemical (PSA) Control and Survival of Different Durations of Adjuvant Androgen Deprivation in Association With Definitive Radiation Treatment for Localised Carcinoma of the Prostate</b>

Trial Chairperson:

**Jim Denham**

Organisation: Calvary Mater Newcastle

Email address: [Jim.Denham@newcastle.edu.au](mailto:Jim.Denham@newcastle.edu.au)

**Phase:**

**Category:** A

Trial Contact:

**Allison Steigler**

Organisation: UoN

Email address: [Allison.Steigler@newcastle.edu.au](mailto:Allison.Steigler@newcastle.edu.au)

**Primary Aim:** To test the hypothesis that 12 months adjuvant androgen deprivation using Leuprorelin acetate starting immediately after standard therapy will reduce prostate cancer-specific mortality when compared with standard therapy alone.

**Final Accrual:** 1206 (Int)/207 (TROG)

**Publications (2018):** Marcello M, Ebert M, Haworth A, Steigler A, Kennedy A, Joseph D, Denham J. Association between treatment planning and delivery factors and disease progression in prostate cancer radiotherapy: results from the TROG 03.04 RADAR trial. Radioth Oncol. 2018 Feb; 126(2):249-56.

#### Closed to Follow-up

**TROG  
02.03**

**Randomised phase III trial of radical chemo/radiotherapy vs radiotherapy alone in the definitive management of localised muscle invasive TCC of the urinary bladder**

Trial Chairperson:

**Kumar Gogna**

Organisation: Princess Alexandra Hospital Raymond Terrace

Email address: [kumar.gogna@health.qld.gov.au](mailto:kumar.gogna@health.qld.gov.au)

**Phase:** III

**Category:** A

**Primary Aim:** To evaluate if a regimen of synchronous weekly Cisplatin and radiation treatment is superior to radical radiation treatment alone in the definitive management of localised invasive TCC of the urinary bladder.

**Final Accrual :** 68

**F/up end date:** 09/02/ 2010

**Publications (2018):** Nil

#### Category C Trial

**TROG N°**

**TITLE**

**LEAD GROUP**

14.01

ENZARAD: Randomised phase 3 trial of radiation plus androgen deprivation therapy with or without enzalutamide for high risk, clinically localised, prostate cancer (ANZUP1303)

NHMRC Clinical  
Trials Centre

## Multiple tumour sites

Trials in Development	
<b>TD 18.07</b>	<b>The Australian Particle Therapy Evidence Generating Network for Rare and Difficult-to-treat cancers</b>

Trial Chairperson:

**Verity Ahern**

Organisation: The Crown Princess Mary Cancer Centre,  
Westmead Hospital

Email address: [Verity.Ahern@health.nsw.gov.au](mailto:Verity.Ahern@health.nsw.gov.au)

Phase: NA

Category: D -Registry

Primary Aim: Particle Therapy registry

Trial Contact:

**Rebecca Montgomery**

Organisation: TROG Cancer Research

Email address: [trials@trog.com.au](mailto:trials@trog.com.au)

Summary of Trial Activity:

eVote

Eol

Protocol  
Plan

Budget

Funding

Trials in Development	
<b>TD 18.02</b>	<b>PPRISM: Paediatric Palliative Radiotherapy in Single or Multiple fractions) / Single vs multiple fraction radiotherapy for palliation in paediatric cancers</b>

Trial Chairperson:

**Greg Wheeler**

Organisation: Peter MacCallam Cancer Centre

Email address: [greg.wheeler@petermac.org](mailto:greg.wheeler@petermac.org)

Phase: II

Category: A

Primary Aim: Pain scale including analgesic usage

Trial Contact:

**Rebecca Montgomery**

Organisation: TROG Cancer Research

Email address: [trials@trog.com.au](mailto:trials@trog.com.au)

Summary of Trial Activity:

eVote

Eol

Protocol  
Plan

Budget

Funding

Open Trial	
<b>TROG 16.03</b>	<b>CORE: A randomised trial of CONventional care versus Radioablation (stereotactic body radiotherapy) for Extracranial oligometastases</b>

Trial Chairpersons:

**Farshad Foroudi | David Pryor**

Organisation: The Austin | Princess Alexandra

Email address: [farshad.foroudi@austin.org](mailto:farshad.foroudi@austin.org) | [david.pryor@health.qld.gov.au](mailto:david.pryor@health.qld.gov.au)

Phase: II

Category: B (Lead Group - ICR)

Primary Aim: To evaluate if the addition of SBRT to standard therapy improves progression free survival outcomes in patients with limited burden of oligometastatic disease

Accrual (Current / Target): 235/230 (Int) | 17/50 (TROG)

Site status: 9 activated / 6 pending

Projected accrual end date: 28/02/2019

Publications (2018): Nil

Trial Contact:

**Courtney Hill**

Organisation: TROG Cancer Research

Email address: [CORE@trog.com.au](mailto:CORE@trog.com.au)